RAPT Therapeutics Inc【RAPT】株式ニュース

個人投資家向けのプロ仕様のツール。

プレミアム

RAPT Therapeutics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Form S-3 - Registration statement under Securities Act of 1933

Form 8-K - Current report

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a...

Form D - Notice of Exempt Offering of Securities

Buy this. Smart money in.

👍️0

tbonaces80 3月前

Gonna breakout above $2.11. Hold for major move. Shares gobbled on this wedge

👍️0

glenn1919 3月前

RAPT......................https://stockcharts.com/h-sc/ui?s=RAPT&p=W&b=5&g=0&id=p86431144783

Wainwright ups price to $10. This will be going parabolic

👍️0

tbonaces80 3月前

We go hard this week. Too many Capital firms bought in. Load the boat $6-$10 easy

👍️0

tbonaces80 3月前

This will hit $6 easily. Analysts know. Huge funding. Foully loaded.

👍️0

PonkenPlonken 3月前

@tbonaces80 @Princess17
What do you two think about this?
150 million pp says massively misunderstood story? 140mn historical volume too...

see chart and compare PP to market cap
must be massively misunderstood

also had a license agreement today
Regards

👍️0

bigbux1 3月前

What am I missing? They just did a private placement of 100,000,000 shares of common stock at a purchase price of $0.85 per share and this soars past 1.50?

👍️0

Mister Mr 3月前

Keep pumping! Let's go!!!

👍️0

glenn1919 3月前

rapt........................https://stockcharts.com/h-sc/ui?s=rapt&p=W&b=5&g=0&id=p86431144783

👍️0

PonkenPlonken 3月前

https://www.globenewswire.com/news-release/2024/12/23/3001133/0/en/RAPT-Therapeutics-Announces-150-Million-Private-Placement.html
wow!
market cap 30 million no discount

👍️0

Invest-in-America 3月前

RAPT:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175569055

👍️0

tw0122 3月前

RAPT up 15% news and TRAW also up $13.77 + 150% TRAW up big

👍️0

glenn1919 3月前

RAPT.........................https://stockcharts.com/h-sc/ui?s=RAPT&p=W&b=5&g=0&id=p86431144783

Bargin prices!! Lets go!!

👍️0

Stockexpertpro 1年前

RAPT Only 1 Patient had a problem out of 350 people enrolled in the trial

https://finance.yahoo.com/news/1-fda-puts-hold-two-125809258.html Fire sale down here lots of upgrades out last weeK

👍️0

StockLogistics 3年前

Surprised that no gap fill occurred prior to results expected near September 12, showing major strength buoyed by estimates of 50.00:

“8:04a ET 5/23/2022 - Benzinga
RAPT Therapeutics Announces Initiation Of Phase 2b Trial Of RPT193 In Patients With Moderate-to-Severe Atopic Dermatitis

RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it has initiated its 16-week randomized, double-blind, placebo-controlled Phase 2b clinical trial to further evaluate the efficacy and safety of RPT193 as monotherapy in patients with moderate-to-severe atopic dermatitis (AD).”

👍️0

StockLogistics 3年前

12.16 gap fill over the next 14.5 weeks

👍️0

StockLogistics 3年前

12.16 gap fill over the next 14.5 weeks

👍️0

StockLogistics 3年前

15 weeks to go

8:04a ET 5/23/2022 - Benzinga
RAPT Therapeutics Announces Initiation Of Phase 2b Trial Of RPT193 In Patients With Moderate-to-Severe Atopic Dermatitis

Countdown to potential billions in revenue.

👍️0

StockLogistics 3年前

A ton of insider buying last week

👍️0

StockLogistics 3年前

Positive sentiment about billions that could be made from Rapt’s drug and pipe financing, perfect storm brewing

👍️0

Glider549 4年前

It happens,,and more often than not doesn't.
That's why I'd trim, but leave some on the table.

👍️0

weasel4339 4年前

It's way up after hours bud

👍️0

Glider549 4年前

Can't believe some of you did not take profits near the close.
Greed will kill ya.

I'll keep n eye out. Let me knoe if u hear something about the price

👍️0

pennyfinder 4年前

Supposed to be. There’s no price set on the offering. They just said they’re raising $125M, they could be raising at $50… who knows… but the history has always been lower than the closing price. We will have to wait and see.

👍️0

weasel4339 4年前

This considered dilution?

👍️0

pennyfinder 4年前

LOL

https://investors.rapt.com/news-releases/news-release-details/rapt-therapeutics-announces-proposed-public-offering-common

👍️0

make it happen 4年前

Most def. Idk how these companies even give a PT like that. Happens way to often and retails get blindsided. I wouldn't even do that if had all the power too.

👍️0

pennyfinder 4年前

Offering AH or tomorrow pre

👍️0

make it happen 4年前

Negative 1,000% plus operating margins. Only Phase 1 still, A long way to go...

Large negative lose percentages across the board on margins.

Only $0.22 revenue per share

Cash flow will burn all money before end of year.

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -1,064.70%

Management Effectiveness
Return on Assets (ttm) -27.62%
Return on Equity (ttm) -50.34%

Income Statement
Revenue (ttm) 5.33M
Revenue Per Share (ttm) 0.22
Quarterly Revenue Growth (yoy) 30.70%
Gross Profit (ttm) 5.04M
EBITDA -55.53M
Net Income Avi to Common (ttm) -56.27M
Diluted EPS (ttm) -2.29

Balance Sheet
Total Cash (mrq) 98.41M
Total Cash Per Share (mrq) 3.93
Total Debt (mrq) N/A
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 9.21
Book Value Per Share (mrq) 3.69

Cash Flow Statement
Operating Cash Flow (ttm) -45.66M
Levered Free Cash Flow (ttm) -23.3M

👍️0

StockLogistics 4年前

This stock reported legitimate results of its study and is a short squeeze candidate imo if Reddit wanted to wake up to it

👍️0

Roadtojourney 5年前

Not even 6 months old and already offering??

👍️0

crudeoil24 5年前

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It is developing selective small molecules designed to modulate the critical immune responses underlying these diseases. It has discovered and advanced two drug candidates FLX475 and RPT193, which is engaged in targeting C-C motif chemokine receptor 4 (CCR4). Its drug discovery and development engine has identified CCR4 as a drug target that potentially has broad applicability in oncology and inflammatory diseases. Its lead oncology drug candidate FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory Treg cells into tumors. Its RPT193 drug candidate, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells), into allergically-inflamed tissues.

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

RAPT Therapeutics Inc (RAPT)

個人投資家向けのプロ仕様のツール。

RAPT ニュース

RAPT Therapeutics to Participate in Upcoming Investor Conferences

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Form S-3 - Registration statement under Securities Act of 1933

Form 8-K - Current report

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

Form D - Notice of Exempt Offering of Securities

RAPT Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

RAPT Therapeutics Inc (RAPT) ニュース

RAPT Therapeutics Inc (RAPT)

個人投資家向けのプロ仕様のツール。

RAPT ニュース

RAPT Therapeutics to Participate in Upcoming Investor Conferences

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Form S-3 - Registration statement under Securities Act of 1933

Form 8-K - Current report

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

Form D - Notice of Exempt Offering of Securities

RAPT Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

広告を削除する